Improvement in prescriptions while maintaining overall health outcomes: a prospective observational study conducted in Japanese facilities for older people

Table 8 Comparison between demographics of the NIG and that of the IG before and after matching

	NIG	IG	Standardized difference
Before matching
Number of people	368	153
Sex women, %	75.00	74.51	0.011
Age years, mean ± SD	86.4 ± 7.9	86.6 ± 8.0	0.025
EQ-5D-5L scores mean ± SD	0.62 ± 0.26	0.59 ± 0.24	0.13
BI scores mean ± SD	60.2 ± 32.2	58.0 ± 33.1	0.067
MMSE scores mean ± SD	17.0 ± 8.9	16.0 ± 8.6	0.12
DBD scores mean ± SD	16.5 ± 14.3	17.9 ± 14.5	0.10
VI scores mean ± SD	7.4 ± 2.6	7.3 ± 2.6	0.055
Medication costs JPY/day, mean ± SD	499.0 ± 598.0	601.1 ± 656.2	0.16
Number of medications mean ± SD	7.6 ± 3.4	8.5 ± 3.8	0.27
After matching
Number of people	275	141
Sex women, %	74.2	75.2	0.023
Age years, mean ± SD	86.2 ± 8.3	86.7 ± 8.1	0.063
EQ-5D-5L scores mean ± SD	0.59 ± 0.26	0.59 ± 0.24	0.026
BI scores mean ± SD	57.7 ± 33.4	57.9 ± 33.2	0.070
MMSE scores mean ± SD	16.2 ± 9.2	16.2 ± 8.5	0.0023
DBD scores mean ± SD	18.0 ± 14.8	17.9 ± 14.3	0.071
VI scores mean ± SD	7.3 ± 2.7	7.3 ± 2.6	0.027
Medication costs JPY/day, mean ± SD	523.1 ± 460.3	560.0 ± 629.6	0.067
Number of medications mean ± SD	8.1 ± 3.4	8.3 ± 3.8	0.059

SD standard deviation, EQ-5D-5L EuroQoL-5D-5L-proxy, BI Barthel Index, MMSE Mini-Mental State Examination, DBD Dementia Behaviour Disturbance Scale, VI Vitality Index
NIG (not improvement group), those who were prescribed both in March 2019 and March 2020 were classified into this group
IG (improvement group), participants who were prescribed and administered medications cautiously in March 2019 and not prescribed in March 2020 were classified into this group

ISSN: 1471-2318